Jerry D Estep, MD; Husam M Salah, MD; Samir R Kapadia, MD; Daniel Burkhoff, MD, PhD; Anuradha Lala, MD; Javed Butler, MD, MPH, MBA; Shelley Hall, MD; Marat Fudim, MD, MHS 

J Card Fail. 2024 DOI: https://doi.org/10.1016/j.cardfail.2024.07.007 
Published September 2024

Top 10 Takeaways

1. Device-based therapies are becoming integral in managing HF
2. This is a rapidly growing field with many devices gaining approval by the regulatory agencies
3. Devices offer a promising avenue to address the high residual risk in HF 
4. Guideline-directed medical therapy includes both drug and selected device-based therapies. 
5. These classes of therapy should be considered synergistic rather than in competition to each other
6. Device based therapies can overcome certain limitations of drug therapy (e.g., adherence and tolerance), and effectively target some of the HF-related pathophysiologic alterations that may not be amenable to pharmacological therapy
7. Device based therapies span both diagnostic and therapeutic approaches 
8. There is a need for better identification of the ideal patient population by employing clinical, hemodynamic, and structural phenotyping of HF
9. There is a need for a systematic approach to integrate device interventions into the HF management workflow through evidence-based sequencing strategies is crucial
10. Device based therapies in HF is a team based discipline that requires in many cases cross-silo collaboration

Heart Failure Beat Interview with Lead Authors

Marat Fudim, MD, MHS discusses the HFSA statement on device-based therapies, including emerging innovations like cardiac contractility modulation and remote monitoring tools on this episode, released in December 2024. Tune In >>

Quick Highlights

Marat Fudim, MD, MHS shares highlights on the HFSA Scientific Statement: Update on Device Based Therapies in Heart Failure. See the highlights in this post >>

@JCardFail is proud to publish this comprehensive Scientific Statement on Devices in #FunctionNotFailure led by @FudimMarat @JerryEstepMD & others.

Check it out! 🔗 https://t.co/wRZYTCNGS3 https://t.co/2FMJGcrFvp pic.twitter.com/1h1EZ0gcxm

— Journal of Cardiac Failure (@JCardFail) September 10, 2024

Press Release

The Case for Integrating Novel Device-Based Therapies into Guideline Directed Medical Therapy for the Treatment of Heart Failure

WASHINGTON, DC (SEPTEMBER 10, 2024) - Novel device-based therapies may overcome limitations of pharmacologic therapies for some patients living with heart failure (HF), indicating that a synergistic approach between the two therapies is ideal for implementation of guideline directed medical therapy (GDMT). The Heart Failure Society of America (HFSA) Scientific Statement: Update on Device Based Therapies in Heart Failure, published today in the Journal of Cardiac Failure (JCF), provides a state-of-the-art scientific overview and update of the rapidly evolving field of device-based therapies for HF, including a clinical pathway to implementation of these technologies alongside pharmacologic therapies. Read the full press release >>